Hanmi Science Hanmi Pharmaceutical obesity drug HM15275 LAPS platform biotech pipeline illustration

Hanmi Science (008930) Stock Outlook 2026: Korean Obesity Drug Play and Governance Reset

Daylongs · May 21, 2026 · 8 min read

#008930 #Hanmi Science #Korean biotech #obesity drug GLP-1 #LAPS platform #HM15275 #Korean pharma #Korean holding company

Korean biotech’s most globally visible drug company is not listed under its own name — it’s accessible through its parent holding company.

Hanmi Science (KOSPI: 008930) holds approximately 43% of Hanmi Pharmaceutical (128940), Korea’s leading LAPS platform drug developer and the company building the obesity drug HM15275 to challenge Ozempic and Mounjaro.

At 31,900 KRW — down 42% from the 52-week high of 55,500 KRW — the holding company discount plus governance risk concerns are priced in. Whether you’re looking at a recovery opportunity or a value trap depends on understanding what’s actually happening in the pipeline.

Corporate Structure: Holding Company Accessing a Drug Pipeline

Hanmi Science (KOSPI: 008930)
  └── ~43% stake in Hanmi Pharmaceutical (KOSPI: 128940)
        ├── Hanmi Fine Chemical (raw materials, APIs)
        ├── Beijing Hanmi Pharmaceutical (China ops)
        └── Other international subsidiaries

Key implication for investors: Hanmi Science’s value is primarily derived from its stake in Hanmi Pharmaceutical. Hanmi Pharmaceutical is the entity that:

Holds the LAPS platform IP
Runs clinical trials for HM15275 and other pipeline candidates
Signs and receives license-out deal payments
Reports drug development progress

Hanmi Science, as a holding company, earns dividends from Hanmi Pharmaceutical and benefits from its share price appreciation — but with the typical 20-40% holding company discount applied by the market.

008930 vs. 128940: Which to Buy?

Investment Goal	Recommended Stock
Direct pipeline exposure	128940 (Hanmi Pharmaceutical)
Holding company discount narrowing thesis	008930 (Hanmi Science)
Clean governance exposure	128940
Double leverage play (pipeline + governance)	008930

Financial Snapshot (May 2026)

Metric	Value	Source
Share price	31,900 KRW	kr.investing.com, May 2026
Market cap	2.11 trillion KRW (~$1.53B)	kr.investing.com
P/E ratio	19.55x	kr.investing.com
P/B ratio	2.19x	kr.investing.com
EPS	1,747 KRW	kr.investing.com
Revenue	1.36 trillion KRW	kr.investing.com
EBITDA	66.45 billion KRW	kr.investing.com
Dividend yield	0.90%	kr.investing.com
52-week range	30,900 – 55,500 KRW	kr.investing.com
ROE	13.1%	kr.investing.com

Verify latest at DART (dart.fss.or.kr) or Hanmi Science IR.

HM15275: Hanmi’s Obesity Drug in a $100B+ Race

Market Context

The obesity drug market in 2026 is dominated by two compounds from two companies:

Drug	Company	Mechanism	Dosing	Weight Loss
Semaglutide (Ozempic/Wegovy)	Novo Nordisk	GLP-1	Weekly injection	~15-17%
Tirzepatide (Mounjaro/Zepbound)	Eli Lilly	GLP-1/GIP dual	Weekly injection	~22%

These drugs are generating tens of billions in annual revenue and have years of supply constraint. The barriers to entry for any meaningful competitor are extremely high — requiring differentiated efficacy, safety profile, or dosing convenience.

Where HM15275 Sits

HM15275 is a GLP-1/GIP dual agonist (same mechanism class as tirzepatide) developed with Hanmi’s LAPS half-life extension technology. The strategic differentiation Hanmi is targeting:

Extended dosing interval: If LAPS can push the half-life sufficiently, monthly injection (vs. weekly for current market leaders) would represent meaningful patient convenience differentiation. A once-monthly obesity drug at comparable efficacy would be commercially significant.

Current clinical stage: Verify via Hanmi Pharmaceutical’s latest DART filings. As of writing, HM15275 has been in clinical development, but we cannot confirm the specific current phase and latest data without direct access to the most recent DART disclosures.

The binary nature: Obesity drug clinical success is either/or — either the Phase 2/3 data show competitive efficacy and the compound attracts a licensing partner, or it doesn’t. Hanmi’s previous experience with large license-out deals (Sanofi, Eli Lilly, BMS partnerships in prior years) demonstrates the company’s ability to execute, though some prior deals were returned to Hanmi after partner reassessments.

LAPS Platform: The Core Technology Asset

How LAPS Works

LAPS (Long Acting Peptide/Protein Solution) is Hanmi Pharmaceutical’s proprietary technology that extends the biological half-life of peptide and protein drugs.

Mechanism: The active peptide (GLP-1, insulin, growth hormone, etc.) is conjugated to an immunoglobulin Fc fragment or PEG-like polymer linker using a site-specific conjugation chemistry. This slows enzymatic degradation and renal clearance.

Applications in the pipeline:

Obesity/diabetes: GLP-1, GIP, glucagon-based compounds
Growth hormone deficiency: LAPSGrowth Hormone (already licensed in some markets)
Neutrophil deficiency (cancer chemo support): LAPSG-CSF
Hemophilia: LAPS-based factor VIII/IX

Why Platform Technology Matters

A platform technology spreads risk across multiple pipeline candidates. If HM15275 fails, the LAPS platform continues to generate value across other indications. If HM15275 succeeds, the validated platform increases partner interest in every other LAPS compound.

This is the key difference between a single-drug biotech and a platform biotech — and why Hanmi Pharmaceutical has historically attracted licensing partners from top-tier global pharma companies.

Governance: The Discount That May Narrow

Background on the Dispute

Following the 2020 passing of Hanmi Group founder Im Sung-ki, a control dispute between his widow Song Young-sook and sons Im Jong-yoon and Im Jong-hoon became public in 2023-2024. The dispute involved share ownership, board composition, and management authority over Hanmi Science and Hanmi Pharmaceutical.

May 2026 Status

We cannot fully verify the current governance resolution status at time of writing. International investors must verify the current board composition, chairman, and any shareholder agreement outcomes via DART filings (most recent annual report, shareholder meeting minutes).

Investment implication: If governance has stabilized and institutional investors return to Hanmi Science, the holding company discount could narrow — providing re-rating upside independent of pipeline progress. If disputes recur or minority shareholders are disadvantaged, the discount will widen.

Competitive Analysis: Can HM15275 Compete?

The honest assessment: competing with Ozempic and Mounjaro is extremely difficult.

Factor	Hanmi Advantage	Hanmi Disadvantage
Dosing frequency (potential monthly)	If validated, clear differentiation	Not yet demonstrated in late-stage trials
Cost structure	LAPS tech may enable competitive pricing	Manufacturing scale significantly below NVO/LLY
Distribution	License partner would bring distribution	Dependent on finding right partner
Patent landscape	Own LAPS IP free from Novo/Lilly IP	Must design around crowded GLP-1 patent space

The licensing partnership model is the key. Hanmi doesn’t need to build global distribution — it needs to convince a Roche, AstraZeneca, Pfizer, or Amgen that HM15275’s monthly dosing advantage is commercially significant enough to invest in late-stage development.

Scenario Analysis

Scenario A — Phase 2/3 Success + Major License-Out (25% probability)

HM15275 Phase 2/3 data demonstrate competitive efficacy and confirmed monthly dosing interval. Major pharma signs license for upfront $500M-$2B+ with milestones. Governance stabilized. Holding company discount narrows to 20%. Stock price recovers to 50,000-65,000 KRW.

Scenario B — Incremental Progress (40% probability)

Clinical trials ongoing. Positive Phase 2 interim data. Governance stable. Stock oscillates 30,000-42,000 KRW. Market awaits Phase 3 initiation with a major pharma partner signal.

Scenario C — Clinical Setback or Governance Shock (35% probability)

HM15275 trial suspension, significant adverse event, or competitive benchmark showing inferiority. Or: governance dispute returns, triggering institutional selling. Stock tests 20,000-25,000 KRW. Platform value partially maintained if LAPS shows value in other indications.

How International Investors Access Hanmi Science

Direct KOSPI Investment

Interactive Brokers: Best route for most international investors seeking direct KOSPI access
Tiger Brokers, Saxo Bank: Korean market access available
No US ADR for either 008930 or 128940

Tax Considerations

Korean dividend withholding: 22% (including local tax), reduced to 15% for treaty countries. With only 0.90% dividend yield, this is a minimal consideration.

Capital gains from Korean equity: Korea generally does not impose capital gains tax on foreign investors for listed equity below certain thresholds (verify current regulations as they can change).

Conclusion

Hanmi Science (008930) is a high-risk, high-potential position that concentrates three uncertainties in one stock: clinical trial binary (HM15275), holding company discount (008930 vs. 128940), and governance resolution (family dispute).

At 31,900 KRW — near the 52-week low — the risk is heavily priced in. But being near the low does not mean the bottom is in. Clinical trial stocks can fall 50-70% on bad data regardless of valuation.

The investment case requires all three of: (1) confidence in LAPS platform generating competitive HM15275 data, (2) belief that governance has stabilized enough for institutional re-entry, (3) willingness to hold through clinical binary events.

Investors who want the obesity drug Korea play without governance risk should consider Hanmi Pharmaceutical (128940) directly. Investors who want the governance discount as an additional return lever can consider 008930 — understanding that both the governance risk and holding company discount are priced in for a reason.

This post is for informational purposes only and does not constitute investment advice. Data sourced from kr.investing.com as of May 2026. Clinical trial stage, governance resolution status, and latest dividends must be verified directly via DART (dart.fss.or.kr). The governance dispute resolution status could not be fully verified at time of writing.

What is Hanmi Science (008930) and how does it relate to Hanmi Pharmaceutical?

Hanmi Science (008930) is the holding company that controls Hanmi Pharmaceutical (128940, KOSPI), Korea's most globally active drug developer. Hanmi Science holds approximately 43% of Hanmi Pharmaceutical. Investing in 008930 provides indirect exposure to Hanmi Pharmaceutical's drug pipeline, primarily the LAPS platform compounds including the obesity drug HM15275.

What are the current financial metrics for Hanmi Science (008930)?

As of May 2026 per kr.investing.com: share price 31,900 KRW, market cap 2.11 trillion KRW (~$1.53B), P/E 19.55x, P/B 2.19x, EPS 1,747 KRW, revenue 1.36 trillion KRW, dividend yield 0.90%, 52-week range 30,900-55,500 KRW, ROE 13.1%. Verify latest via DART (dart.fss.or.kr) or Hanmi Science IR.

What is the obesity drug HM15275 and where is it in clinical development?

HM15275 is Hanmi Pharmaceutical's GLP-1/GIP dual agonist obesity drug candidate, developed using the proprietary LAPS (Long Acting Peptide/Protein Solution) platform. It competes in the same class as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). LAPS technology aims to extend the drug's half-life, potentially enabling monthly dosing vs. current weekly alternatives. Current clinical stage must be verified via Hanmi Pharmaceutical's latest DART filings.

What is the LAPS platform?

LAPS (Long Acting Peptide/Protein Solution) is Hanmi Pharmaceutical's proprietary half-life extension technology. It conjugates peptide/protein drugs with immunoglobulin Fc fragments or PEG-like linkers to slow degradation in the body. The platform applies across multiple drug modalities: GLP-1/GIP (obesity/diabetes), growth hormone, G-CSF (neutrophil deficiency), and others. It is a platform technology, not a single drug — meaning multiple pipeline candidates leverage the same core IP.

What was the family governance dispute at Hanmi Science and has it been resolved?

Following the death of Hanmi Group founder Im Sung-ki in 2020, a control dispute emerged between his widow Song Young-sook (chairman) and his sons Im Jong-yoon and Im Jong-hoon, among others. The dispute involved share ownership and management authority over Hanmi Science and Hanmi Pharmaceutical. As of May 2026, the governance situation should be verified via the most recent DART filings (annual report, shareholder meeting results). We were unable to fully verify the final resolution status at time of writing.

Why has Hanmi Science's stock fallen from the 52-week high of 55,500 KRW to ~31,900 KRW?

The 52-week range of 30,900-55,500 KRW represents ~42% drawdown from peak. Contributing factors likely include: governance uncertainty discount expanding during dispute periods, market recalibration of obesity drug pipeline timeline expectations, and sector-wide biotech valuation compression. Individual event-specific causation should be verified through DART announcements at the relevant times.

How can international investors buy Hanmi Science (008930) stock?

008930 trades on KOSPI in Korean Won. International access: Interactive Brokers (direct KOSPI access), iShares MSCI South Korea ETF (EWY) for indirect exposure, or Tiger Brokers / Saxo Bank for Korean market access. No US ADR exists for either Hanmi Science (008930) or Hanmi Pharmaceutical (128940). For more direct drug pipeline exposure without holding company discount, 128940 is the alternative.

Is it better to invest in Hanmi Science (008930) or Hanmi Pharmaceutical (128940) directly?

Hanmi Pharmaceutical (128940) provides more direct exposure to the drug pipeline with less holding company discount. Hanmi Science (008930) adds governance risk, holding company discount (typically 20-40% vs. NAV), and the specific governance situation. If the primary thesis is HM15275 or LAPS platform success, 128940 is the cleaner play. 008930 makes more sense if you believe the governance discount will narrow — providing double leverage upside.

What are the main risks for Hanmi Science investors?

① HM15275 clinical trial failure or significant setback ② Ongoing or renewed governance uncertainty reducing institutional willingness to hold ③ Competitive disadvantage vs. Novo Nordisk and Eli Lilly's entrenched obesity drugs ④ Cash depletion before licensing deal closes ⑤ Holding company discount widening ⑥ Broader Korean biotech sector de-rating.

What is a license-out deal and why does it matter for Hanmi Science?

A license-out (technology transfer) is when Hanmi Pharmaceutical licenses its drug candidate to a global pharma company (e.g., Sanofi, Eli Lilly, J&J) for upfront payments, milestones, and royalties. Historically, Hanmi secured multi-billion dollar license agreements (Sanofi deal for insulin analog, etc.). A successful HM15275 license-out would generate substantial upfront cash and validate the LAPS platform — the scenario the market is primarily pricing in.

What is Hanmi Pharmaceutical's global strategy?

Hanmi Pharmaceutical's core strategy is to develop LAPS platform-based compounds through Phase 1-2 clinical trials and license them to global pharma partners for late-stage development and commercialization. This asset-light model allows Hanmi to generate upfront milestone payments without bearing full Phase 3 costs. Past major deals include Sanofi (insulin analogs), Bristol Myers Squibb, and others, though some were returned to Hanmi.

Hanmi Science (008930) Stock Outlook 2026: Korean Obesity Drug Play and Governance Reset